← Leaderboards
William H Kutteh
University Of Tennessee Health Sci Ctr
$30,097
Attributed
$30,097
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.7K · FY2005–06$5K$3.8K$2.5K$1.3K$0
'05
'06
Funding mix
By agency
NIH$30,097 · 3
By mechanism
M01$30,097 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Gabor J Tigyi$24,190,037
- Linda K. Myers$3,788,393
- Donna K. Hathaway$4,924,717
- Eldon E Geisert$9,914,911
- Rebecca P. Winsett$2,031,899
Others in their field
Top investigators on “Women'S Health”
- Chanza Baytop · Westat, Inc.$271,217,917
- Wafaa M. El-Sadr · Columbia University Health Sciences$240,499,512
- Sharon A Nachman · Johns Hopkins University$213,337,729
- Myron S Cohen · Family Health International$206,489,087
- Barbara Driver · Westat, Inc.$200,651,985
- Carol Nesel · Westat$188,148,170
Research focus
Women'S HealthClinical ResearchDrug Screening /EvaluationHuman SubjectSalivaFemale Reproductive SystemMicroorganism Disease ChemotherapyMucosal ImmunityPatient Care PlanningHormone Regulation /Control MechanismDisease /Disorder Prevention /ControlBehavioral /Social Science Research TagBlood ChemistryCervical /Vaginal SmearImmunizationSexually Transmitted DiseasesImmunosuppressiveImmunoglobulinsChronic Spontaneous AbortionClinical TrialsFemaleAssistive Reproductive TechniqueChronic Disease /DisorderImmunotherapy
Grant awards (5)
IMMUNE GLOBULIN INTRAVENOUS (HUMAN) 10% WITH PLACEBO IN THE TREATMENT OF RSA$4,323
M01 · FY2006 · RR · contact PI
IMMUNE GLOBULIN INTRAVENOUS (HUMAN) 10% WITH PLACEBO IN THE TREATMENT OF RSA$4,664
M01 · FY2005 · RR
Immune Globulin Intravenous (Human) 10% with Placebo in the Treatment of RSA$4,768
M01 · FY2004 · RR
MUCOSAL STRATEGIES FOR GENERAL IMMUNITY AGAINST SEXUALLY TRANSMITTED DISEASE$0
M01 · FY2001 · RR
MUCOSAL STRATEGIES FOR GENERAL IMMUNITY AGAINST SEXUALLY TRANSMITTED DISEASE$16,342
M01 · FY2000 · RR